Dr. Schuehsler has dedicated his career to exploring new horizons as an investor, pursuing innovation and building teams and businesses, sometimes from scratch, sometimes in new regions, and always in healthcare and with an eye on products or services that address unmet medical needs and promote societal progress. In the process he has gained extensive operating and investment experience across continents, catalyzing healthcare innovation in West and East.

He started his investment management career at Horizonte Venture Management in Vienna, Austria, and joined TVM Capital in Munich in 1990. During his tenure with the TVM Capital group of companies, Dr. Schuehsler started biotech investing in Germany and made TVM Capital the leading and largest life science investor in Germany, led the development of the firm into one of the leading pan-European investors and started the life science activities in the Boston office in 1998. In Boston, TVM Capital was for many years among the top ten investors in life sciences on the East Coast. Starting in 2007, he spearheaded the creation of TVM Capital Healthcare which was domiciled in Dubai in 2009 and expanded to Singapore in late 2018.

Dr. Schuehsler has been the deal leader on more than 35 direct investments in life science and healthcare companies in Europe, the U.S., the Middle East and India. In total he has raised more than US$1bn in committed capital from more than 50 international investors, has overseen more than 120 investments in the health market, and more than 50 IPOs and 30 M&A exit transactions in the portfolio. Currently, Dr. Schuehsler is a director at Human Longevity Inc. (San Francisco, San Diego, and Beijing), a leader in longevity medicine built by the pioneers of the human genome sequencing effort, leveraging advanced genomics, imaging, and data analysis with a 10,000+ longitudinal patient dataset backed by over a decade of research, and he is director at the F-star Group of Companies (Boston, Vienna, and Cambridge, UK), bispecific antibody companies with a focus on immuno-oncology. He is also Vice-Chairman of the Board of Apeiron Biologics, Vienna. Previously he held the positions of interim CEO and chairman at ProVita International Medical Center, which saw a hugely successful exit to NMC Health plc in mid-2015 and of Cambridge Medical and Rehabilitation Center (CMRC), the leading post-acute and rehabilitation provider in the MENA region, founded by TVM Capital Healthcare in 2012, successfully exited in 2021.

In 2007 and 2008, Dr. Schuehsler served as chairman of the European Private Equity and Venture Capital Association (EVCA, now “Invest Europe”). In 2014-2017, he served on the Steering Committee of the MENA Private Equity Association. He served as a member of the board of Max-Planck Innovation GmbH for more than 10 years and was a member of the Selection Committee for the Technology Pioneers program, the Steering Committee of the Entrepreneurship and Successful Growth Research Program of the World Economic Forum in 2009-2012.

Hoda Abou-Jamra is the Founding Partner and Managing Director Asia of TVM Capital Healthcare in Singapore. In 2007, Hoda was the driving force behind the establishment of TVM Capital Healthcare in the MENA region. She later expanded the business to Singapore to improve access to affordable quality healthcare in Southeast Asia.

Her global expertise in business development and fundraising has helped her to build and develop a successful healthcare-dedicated private equity firm which combines strong commercial value creation with measurable impact creation in its core Sustainable Development Goals (SDGs) of access to care, job creation, and diversity and inclusion.

Hoda currently holds board positions at Manzil Healthcare Services, headquartered in Abu Dhabi, UAE and Amecath Medical Technologies, a medical devices company.

Hoda is also the chairperson of Alina Vision, an ophthalmology hospital group based in Vietnam. She is a regular speaker and commentator in the private equity and healthcare arena and is a major advocate of impact investing and promoting diversity and gender equality within finance.

Hoda is a member of 100 Women in Finance, PEWIN and was a founding Chair of the 30% Club’s MENA chapter, working with multi-sector leaders to achieve even representation of women on boards and in senior level positions. She is a member of WBL Women Leading in Healthcare and of the Dubai Business Women Council, and a member of PhiSB, an invitation only network of females who are exceptional in their potential, achievements and drive to make positive impact.

Hoda is also leading the firm’s active contributions to 2X Global, in order to support gender-smart investing. Hoda has also been appointed to the International Advisory Council (IAC) of Mass General, the largest teaching hospital of Harvard Medical School in Boston, USA. The International Advisory Council (IAC) at Mass General brings together global industry and thought leaders with significant experience and perspective on international business and policy. Before co-founding TVM Capital Healthcare, she was the CEO of Boston BioCapital, a U.S.-based firm that provided strategic advice, due diligence services, business plan conception, business development and consulting services within the U.S. and European biotech industries. She is also a founder of The BioExec Institute, Boston, a non-profit think tank for the healthcare industry.

Hoda graduated from the Bouve College of Health Sciences, Northeastern University in Boston, with a degree in Pharmacy.

40 years of experience in private equity, corporate finance and management consulting​

 Founder and Managing Director of Titan Capital; Former Chairman of the Board of Pacific Internet​

Co-founding Partner and former Managing Director of TPG Capital Asia; built from USD 100 million to USD 6 billion dollars of capital under management​

Founder and Principal of the Asian arms of A.T. Kearney and Booz Allen Hamilton; Former CEO of Ometraco Corporation​

MBA, MS, Columbia University; BS (Hons), Engineering, Birmingham University​

Ghida Harfouche has over 19 years of experience across the investment, pharmaceutical and healthcare sectors, coupled with a strong consulting expertise.

Her responsibilities include sourcing, evaluating and executing on new investment opportunities, performing financial and operational due diligence, fund reporting, as well as being actively involved in fundraising activities. She also actively participates in portfolio management, including the strategic expansion planning for portfolio and affiliated companies as well as developing exit strategies and working on exit readiness.

In a previous tenure, Ghida was a Senior Strategy Consultant at Stem-Pharma. Her role encompassed formulating effective market entry strategies, conducting feasibility and M&A analyses, leading the client relationship across Europe, and providing investment advisory services to a variety of regional and European clients.

In addition to her experience in life science consulting, Ghida has a rich scientific research background focused on pioneering novel target identification. She worked in R&D and clinical research at ‘Institut National de la Santé et de la Recherche Médicale’ (INSERM) and ‘Commissariat à l’Energie Atomique’ (CEA) in France. She received several awards during international scientific conferences. Her research findings have been published in a number of international peer-reviewed journals and she has developed a patent in oncology and photo-protection.

Ghida earned a distinguished PhD in Pharmacology, Cell and Molecular Biology from the University of Paris-Sud XI, France. Complementing her scientific acumen, she holds an MBA from Ecole Supérieure des Affaires, Lebanon, and a DESM (Diplôme d’Etudes Supérieures en Management) from ESCP-Europe, France.

Joining our Southeast Asia investment team soon.

Jannie Tsuei is a Partner in the Singapore office with a decade of transaction experience in Southeast Asia.  Prior to joining us, she led Southeast Asia healthcare investment banking at Morgan Stanley, where she drove healthcare coverage, origination, and execution efforts in the region.  She also served as Chief Operating Officer of the Southeast Asia investment banking at Morgan Stanley from 2018 to 2020. Jannie has been integrally involved in c. US$70Bn of strategic and capital transactions across North America, Asia-Pacific, and Europe.

 

Previously, Jannie worked at Sears Holdings Corporation in a general management rotational program. 

 

Jannie holds an A.B. in literature (magna cum laude) from Harvard College and holds an MBA in Finance (cum laude) from The Wharton School, the University of Pennsylvania.

Orhan Osmansoy has over 20 years of experience in the fields of private equity, merchant banking, and equity capital markets at leading financial services firms. Prior to his current role he was a Managing Director at Frontier Management Group, where he worked with the broader team at Apollo Global Management to source and evaluate private equity and private credit transactions and present investment ideas across a wide range of transaction types including leveraged buyouts, mezzanine financings, and structured purchases.

 

Prior to joining Frontier, Orhan held Board-level and senior responsibility for NAC Ventures SPC, a Kuwaiti creditor-owned restructuring SPV. He had oversight of NAC’s USD 700 million portfolio, with responsibility for the restructuring and monetization of assets including direct investments, listed equities, real estate, and private fund holdings.

 

Previously, he was Chief Executive Officer of The National Investor (TNI), an Abu Dhabi-based merchant banking institution. As CEO of TNI, he positioned the firm among the leading investment management and advisory companies in the GCC and focused the institution on four key areas comprising private equity, investment banking, asset management, and principal investing. Orhan was a Managing Director at Dexter Capital Group, a London-based investment firm that specializes in strategic block investments in Europe where he was responsible for the origination and execution of activist and special situations investments. Earlier in his career, Orhan was a Senior Investment Associate at J.H. Whitney, a US private equity firm where he focused on late-stage venture capital investments and leveraged buyouts in Europe.

 

Orhan began his career at Morgan Stanley where he was a member of both the equity derivatives and corporate finance groups in New York and London.  In this capacity he structured and placed a number of equity-linked derivative products and worked on various financial buyer transactions including reverse LBOs/IPOs, public and private placements of equity securities and high yield debt offerings. Orhan is a graduate of the Wharton School of the University of Pennsylvania (MBA) and the University of Virginia (BS).

Ngoc Anh has 10 years working experience in deal advisory service and investments and was involved in a number of deals across various industries and phases of investment.

 

She established a track record of sourcing, negotiating, executing, and exiting deals in Vietnam and SEA at Phoenix Holdings – a Family Office in Vietnam. As a Board Member of companies, Ngoc Anh has been working closely with management teams on value creation by helping in regional expansion, fundraising, exits.

 

Prior to that, she was Manager at PwC Vietnam and Grant Thornton Vietnam, advising clients in different countries on various stages of a deal cycle from financial modelling, valuation, due diligence, amongst others.

 

Ngoc Anh is a member of the Association of Chartered Certified Accountants (ACCA) and holds a Bachelor Degree in Corporate Finance from University of Economics HCM City. 

Nikhil Jham is a member of the corporate finance team where is focused on the initial assessment of new deals, the development of business plans and due diligence. He works closely with portfolio company Manzil Healthcare Services, supporting the execution of the corporate strategy.

 

Prior to his current tenure, he spent five years in various roles in the Analytics group at ITG, an agency-only brokerage in New York City where he leveraged research, analytics and industry insights to help clients come up with customized trading strategies that minimized costs while meeting their investment objectives.

 

He holds a Bachelor of Science in Finance from the University of Virginia.

Tarek Mezher joined us as a Senior Financial Analyst with a focus on the MENA region, with over five years of experience in the banking sector in corporate and project finance. His responsibilities include sourcing investment opportunities and liaising with management teams, as well as supporting in the assessment, analysis, due diligence, and transaction management.

Prior to his current tenure, he spent five months at the European Bank for Reconstruction and Development (EBRD), London, in the Portfolio Management team focusing on Energy financing and equity investments. He also spent five years at Bank Audi, Lebanon, in the group corporate banking team focusing on project financing and syndication deals within the real estate, construction and energy sectors in the MENA region. His role entailed growing banking relationships with local and regional clients, providing them with tailored financial products, developing financing transaction structures, assessing investment opportunities, and managing the financing of projects.

Tarek holds an MBA from HEC Paris – France, and a Master of Civil Engineering from École Supérieur des Ingénieurs Beirut (USJ) – Lebanon.